ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPG · XNASCIK 2023311fmd_1YA04FKSB494N780MWZ9NGH20HManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2022 to Dec 31, 2025, 4 periods
Latest annual · FY2024
Millions- Total revenues
- 981
- Gross profit
- 952
- Net income
- (405)
- Free cash flow
- (136)
Daily close · AAPGIEX trades only
Nov 09, 2026 to Nov 10, 2026 · 2 sessions15.89 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | CN¥980.7 million | CN¥222 million | +341.8% | 20-F 2025-04-16 · proof |
| Gross profit | CN¥951.6 million | CN¥191.4 million | +397.1% | 20-F 2025-04-16 · proof |
| Net income | -CN¥405.4 million | -CN¥925.6 million | 20-F 2025-04-16 · proof | |
| Cash from operating activities | -CN¥111.4 million | -CN¥726.1 million | 20-F 2025-04-16 · proof | |
| Free cash flow | -CN¥135.6 million | -CN¥772.2 million | 20-F 2025-04-16 · proof | |
| Total assets | CN¥2.6 billion | CN¥2.5 billion | +4.7% | 20-F 2025-04-16 · proof |
| Total liabilities | CN¥2.3 billion | CN¥2.4 billion | -3.5% | 20-F 2025-04-16 · proof |
| Cash and cash equivalents | CN¥893.1 million | CN¥1 billion | -14% | 20-F 2025-04-16 · proof |
| Total debt | CN¥1.7 billion | CN¥1.8 billion | -6.4% | 20-F 2025-04-16 · proof |
- What was ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)'s revenue in fiscal 2024?
- ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported revenue of CN¥980.7 million for fiscal 2024 (the year ended Dec 31, 2024), against CN¥222 million the year before (+341.8%). Source: the 20-F filed with the SEC on Apr 16, 2025. SEC
- What was ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)'s gross profit in fiscal 2024?
- ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported gross profit of CN¥951.6 million for fiscal 2024 (the year ended Dec 31, 2024), against CN¥191.4 million the year before (+397.1%). Source: the 20-F filed with the SEC on Apr 16, 2025. SEC
- What was ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)'s net income in fiscal 2024?
- ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported net income of -CN¥405.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -CN¥925.6 million the year before. Source: the 20-F filed with the SEC on Apr 16, 2025. SEC
- What was ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)'s cash from operating activities in fiscal 2024?
- ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported cash from operating activities of -CN¥111.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -CN¥726.1 million the year before. Source: the 20-F filed with the SEC on Apr 16, 2025. SEC
- What was ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)'s free cash flow in fiscal 2024?
- ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported free cash flow of -CN¥135.6 million for fiscal 2024 (the year ended Dec 31, 2024), against -CN¥772.2 million the year before. Source: the 20-F filed with the SEC on Apr 16, 2025. SEC
- What are ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)'s total assets?
- As of Dec 31, 2024, ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported total assets of CN¥2.6 billion, against CN¥2.5 billion a year earlier (+4.7%). Source: the 20-F filed with the SEC on Apr 16, 2025. SEC
- What are ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)'s total liabilities?
- As of Dec 31, 2024, ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported total liabilities of CN¥2.3 billion, against CN¥2.4 billion a year earlier (-3.5%). Source: the 20-F filed with the SEC on Apr 16, 2025. SEC
- What are ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)'s cash and cash equivalents?
- As of Dec 31, 2024, ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported cash and cash equivalents of CN¥893.1 million, against CN¥1 billion a year earlier (-14%). Source: the 20-F filed with the SEC on Apr 16, 2025. SEC
- What is ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)'s total debt?
- As of Dec 31, 2024, ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported total debt of CN¥1.7 billion, against CN¥1.8 billion a year earlier (-6.4%). Source: the 20-F filed with the SEC on Apr 16, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:AAPG&period_type=annual&limit=5"Information only, not investment advice.